Q2 EPS Estimate for Cadrenal Therapeutics Raised by Analyst

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at HC Wainwright upped their Q2 2026 EPS estimates for Cadrenal Therapeutics in a research report issued on Tuesday, July 21st. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.95) for the quarter, up from their previous forecast of ($1.33). HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($5.25) per share. HC Wainwright also issued estimates for Cadrenal Therapeutics’ Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($3.19) EPS and FY2027 earnings at ($3.09) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.47.

CVKD has been the topic of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Trading Up 0.5%

CVKD stock opened at $2.04 on Thursday. The firm has a 50 day moving average of $3.57 and a 200-day moving average of $5.43. The company has a market cap of $6.32 million, a price-to-earnings ratio of -0.36 and a beta of 1.73. Cadrenal Therapeutics has a 12-month low of $1.86 and a 12-month high of $14.64.

Insider Buying and Selling at Cadrenal Therapeutics

In related news, CEO Quang X. Pham sold 12,996 shares of Cadrenal Therapeutics stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $3.94, for a total transaction of $51,204.24. Following the completion of the transaction, the chief executive officer directly owned 136,381 shares in the company, valued at $537,341.14. The trade was a 8.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 97,500 shares of company stock worth $388,290. Company insiders own 26.09% of the company’s stock.

Hedge Funds Weigh In On Cadrenal Therapeutics

Several hedge funds have recently bought and sold shares of CVKD. Geode Capital Management LLC raised its holdings in shares of Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Cadrenal Therapeutics during the third quarter valued at $103,000. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the 3rd quarter worth about $274,000. Finally, DRW Securities LLC purchased a new stake in Cadrenal Therapeutics during the 4th quarter worth about $171,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.